Overview

• Biopharmaceutical royalty buyer's Q4 Portfolio Receipts grew 18% yr/yr

• Adjusted EBITDA for Q4 beat analyst expectations

• Company repurchased 37 mln shares for $1.2 bln in 2025

Outlook

• Royalty Pharma expects 2026 Portfolio Receipts to be $3,275 mln to $3,425 mln

• 2026 Royalty Receipts expected to grow 3% to 8%

• Operating costs as a percentage of Portfolio Receipts to decrease in 2026

Result Drivers

• DIVERSIFIED PORTFOLIO - Growth in Portfolio Receipts driven by Voranigo, Trelegy, Tremfya, and cystic fibrosis franchise

• CAPITAL DEPLOYMENT - Deployed $2.6 bln on royalty transactions, including a partnership with Revolution Medicines

• INTERNALIZATION MILESTONE - Successful internalization of external manager expected to reduce costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Royalty Pharma PLC is $49.50, about 12% above its February 10 closing price of $44.21

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nGNX7yr9BK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)